Jinhee Jo

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>

Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette et al. · Open Forum Infectious Diseases · 2021 · 57 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with <i>Clostridioides difficile</i> Infection: A Phase 2a Multicenter Clinical Trial

Kevin W. Garey, Jacob McPherson, An Q Dinh et al. · Clinical Infectious Diseases · 2022 · 38 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109

Kevin W. Garey, Jinhee Jo, Anne J Gonzales-Luna et al. · JAMA Network Open · 2023 · 28 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of <i>Clostridioides difficile</i>

Eugénie Bassères, Taryn A Eubank, Khurshida Begum et al. · Antimicrobial Agents and Chemotherapy · 2024 · 19 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +7

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life

Richard L. Hengel, Claudia P. Schroeder, Jinhee Jo et al. · Journal of Patient-Reported Outcomes · 2022 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13